Worldquant Millennium Advisors LLC Has $15.57 Million Position in Royalty Pharma plc (NASDAQ:RPRX)

Worldquant Millennium Advisors LLC increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 49.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 610,173 shares of the biopharmaceutical company's stock after purchasing an additional 201,648 shares during the quarter. Worldquant Millennium Advisors LLC owned approximately 0.10% of Royalty Pharma worth $15,566,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in RPRX. Two Sigma Advisers LP grew its holdings in Royalty Pharma by 21.1% during the 4th quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock worth $93,703,000 after acquiring an additional 640,000 shares during the last quarter. State of Wyoming grew its holdings in Royalty Pharma by 129.5% during the 4th quarter. State of Wyoming now owns 15,096 shares of the biopharmaceutical company's stock worth $385,000 after acquiring an additional 8,518 shares during the last quarter. Sherbrooke Park Advisers LLC grew its holdings in Royalty Pharma by 1.1% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock worth $890,000 after acquiring an additional 380 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in Royalty Pharma during the 4th quarter worth approximately $506,000. Finally, Quantinno Capital Management LP grew its holdings in Royalty Pharma by 30.0% during the 4th quarter. Quantinno Capital Management LP now owns 73,380 shares of the biopharmaceutical company's stock worth $1,872,000 after acquiring an additional 16,945 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Up 0.5%

Shares of NASDAQ:RPRX traded up $0.17 during trading on Tuesday, reaching $32.62. The stock had a trading volume of 813,023 shares, compared to its average volume of 4,657,579. The firm's fifty day moving average is $32.38 and its 200 day moving average is $30.26. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.31. The stock has a market cap of $18.80 billion, a price-to-earnings ratio of 22.50, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The company had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. As a group, equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio is currently 47.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RPRX shares. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. Finally, Morgan Stanley started coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They issued an "overweight" rating and a $51.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.